about
Burkitt lymphoma in Brazil is characterized by geographically distinct clinicopathologic features.Relationship of Epstein-Barr virus and interleukin 10 promoter polymorphisms with the risk and clinical outcome of childhood Burkitt lymphoma.Quantitative analysis of CDKN2A methylation, mRNA, and p16(INK4a) protein expression in children and adolescents with Burkitt lymphoma: biological and clinical implications.Pediatric lymphomas in Brazil.NFAT2 Isoforms Differentially Regulate Gene Expression, Cell Death, and Transformation through Alternative N-Terminal Domains.Frequent expression of multiple myeloma 1/interferon regulatory factor 4 in Burkitt lymphoma.miR-17-92 cluster components analysis in Burkitt lymphoma: overexpression of miR-17 is associated with poor prognosis.Dual inhibition of histone deacetylases and phosphoinositide 3-kinases: effects on Burkitt lymphoma cell growth and migration.Osteopontin splice variants expression is involved on docetaxel resistance in PC3 prostate cancer cells.Deregulation of DNMT1, DNMT3B and miR-29s in Burkitt lymphoma suggests novel contribution for disease pathogenesis.Histone deacetylase inhibitor prevents cell growth in Burkitt's lymphoma by regulating PI3K/Akt pathways and leads to upregulation of miR-143, miR-145, and miR-101.Histone deacetylase inhibitor potentiates chemotherapy-induced apoptosis through Bim upregulation in Burkitt's lymphoma cells.p53 flow cytometry evaluation in leukemias: correlation to factors affecting clinical outcome.Insights into apoptosis mechanisms induced by DNA-damaging agents in Burkitt's lymphoma cells.Translocation (11;11)(p13- p15;q23) in a child with therapy-related acute myeloid leukemia following chemotherapy with DNA-topoisomerase II inhibitors for Langerhans cell histiocytosis.An unusual long-term outcome of a child with primary myelofibrosis harboring a JAK2 mutation.Circulating cell-free and Epstein-Barr virus DNA in pediatric B-non-Hodgkin lymphomas.Epstein-Barr virus (EBV) detection and typing by PCR: a contribution to diagnostic screening of EBV-positive Burkitt's lymphoma.Treatment of children with B-cell non-Hodgkin's lymphoma in developing countries: the experience of a single center in Brazil.Geographic variation in Epstein-Barr virus-associated Burkitt's lymphoma in children from Brazil.Modulation of reactive oxygen species by antioxidants in chronic myeloid leukemia cells enhances imatinib sensitivity through survivin downregulation.MiR-29 silencing modulates the expression of target genes related to proliferation, apoptosis and methylation in Burkitt lymphoma cells.DNA sequence profile of TP53 gene mutations in childhood B-cell non-Hodgkin's lymphomas: prognostic implications.Retinoblastoma-related geneRb2/p130 are rarely mutated in Burkitt's lymphoma from Brazil.Burkitt lymphoma/leukaemia transformed from a precursor B cell: clinical and molecular aspects.Coexpression of p53 protein and MDR functional phenotype in leukemias: the predominant association in chronic myeloid leukemia.Lymphoma subtype incidence rates in children and adolescents: First report from BrazilIKZF1 deletion and co-occurrence with other aberrations in a child with chronic myeloid leukemia progressing to acute lymphoblastic leukemiap53 gene analysis in childhood B non-Hodgkin's lymphomaM-BCR rearrangement in a case of T-cell childhood acute lymphoblastic leukemiaLong-term outcome of children and adolescents treated with the COPP-ABV hybrid protocol for Hodgkin's disease: balance of risksPlasma Epstein-Barr viral load predicting response after chemotherapy for post-transplant lymphoproliferative diseaseLangerhans cell histiocytosis: differences and similarities in long-term outcome of paediatric and adult patients at a single institutional centre
P50
Q33835215-5AE5660D-6AF0-4038-8D53-749981E3752EQ34430587-185523D3-70C9-4A1D-95B3-47B294E257D6Q34455781-965BBD0E-0946-4042-B197-9084DF17F98FQ34486959-9A992747-6028-4151-AE32-7B66E0DEBDACQ36434003-67D6B3B2-20E2-4E53-9413-D470EBB1F4C5Q37340329-4D7E45A5-7D83-4000-B0F7-BEF54EA2A056Q38780780-B7692A08-76D3-4123-AA57-9431285E2921Q38819975-4828C158-FF37-4421-9C21-F18A1214C06BQ38832738-C9A06314-AFBB-44CC-B173-18692C38060FQ38902837-DAA961BC-DE68-4B8C-B124-7D8FC036079AQ39020172-3C2D20C2-69D1-4732-9068-13BD08B56649Q39434896-D067E1E2-00C3-4C44-A2F6-EFACCD829E24Q39732888-0DB0A743-A606-4878-A77C-0740D69F3DFEQ39832811-B0C992C0-B541-4024-B775-7EB697C31652Q40580381-939081A2-2826-4725-9FFF-B3926E21B90AQ40955709-D73D8895-5656-4636-B681-8A937C834731Q43063274-3FDDCDAC-DE34-42F5-A03C-22365B61B93FQ43087256-F46F1AF0-EF80-43C6-BE4A-0B6E3D515B2EQ44952363-D8FED747-05E7-4601-86AE-B6F76AEBA5F1Q45709658-99B55581-6044-4FC3-B8A6-04760A1E249BQ46338141-BE3EC407-0427-423E-B1A0-307D1A478184Q47215137-BA56A005-E74F-4836-B3EF-974DFFFE0C06Q47725050-83F1D83A-42DF-47B2-9308-0C159066C63BQ52573343-BDB27C2A-7A0C-434B-8482-B2066424833AQ53327094-782839AA-3A43-4E07-B5D6-62D919302714Q53886209-D0F0A8A9-F761-493A-AABF-A773A6DD9584Q58855514-CEEDFD31-9C9B-4508-A8F4-6D49D9DCE031Q64042317-363DD7B4-6761-4E1A-8812-1467FD4CD72FQ77293293-7428EB8E-4692-4A23-8A82-69B11C29F37FQ77843585-481C8B6B-FA2E-4A95-A804-5FDFA7136CA1Q80699452-71985BAD-F1C8-41B2-AD96-78084F094C3BQ81621964-B5016958-40C9-496E-9D83-484CAC99A1D9Q87979306-097E7314-9987-4CEB-8B4C-1BE577BFAE39
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Claudete Esteves Klumb
@ast
Claudete Esteves Klumb
@en
Claudete Esteves Klumb
@es
Claudete Esteves Klumb
@nl
Claudete Esteves Klumb
@sl
type
label
Claudete Esteves Klumb
@ast
Claudete Esteves Klumb
@en
Claudete Esteves Klumb
@es
Claudete Esteves Klumb
@nl
Claudete Esteves Klumb
@sl
prefLabel
Claudete Esteves Klumb
@ast
Claudete Esteves Klumb
@en
Claudete Esteves Klumb
@es
Claudete Esteves Klumb
@nl
Claudete Esteves Klumb
@sl
P106
P21
P31
P496
0000-0002-7672-1088